About the Guests Jane Lamerdin is VP of R&D at Eurofins DiscoverX, where she oversees development of industry experience across diverse cell-based assays, supporting client drug discovery campaigns, method development At Eurofins DiscoverX, Agrawal leads market development for the cell-based assay portfolio and supports through potency testing and lot release Community and client feedback as the real engine of new product development

Broichhagen reveals how fluorescent probes transform GPCR imaging, internalization studies, and assay development Balanced creativity in tool development with the pressure for reproducible, publication-grade data. research group at the Leibniz Research Institute for Molecular Pharmacology (FMP) in Berlin, focusing on developing

has over 20+ years of experience working in a drug discovery environment mainly in a specialist assay development His current interests include the development of HTS fluorescence-based kinetic binding assays specifically

Pierre Eftekhari "Clinical physiologist and biologist , with more than 25 years of experience in drug development I have participated and initiated methodologies for development of pharmacologically active anti-GPCR

This was followed by a postdoctoral role at the Polytechnic University of Turin (Italy), where he developed Now in a tenure-track position, his research spans the development of computational methods such as structure-based

My project involved the development of FRET/BRET -based GPCR conformational biosensors, which can be I spent 2 1/2 years in his lab and developed novel conformational sensors for these intriguing receptors

Ben’s research focuses on Smoothened and other class F GPCRs which play essential roles in embryonic development within the primary cilium, a tiny antenna-shaped structure at the cell surface with critical links to development Ben studied developmental and cancer signaling as a postdoctoral fellow with Philip Beachy at Stanford

identification of small molecule regulators of these proteins, and progressing such ligands in drug development non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics (2020) which is developing

Organizers Eurofins DiscoverX Eurofins DiscoverX is a one-stop-shop for GPCR drug discovery and development scientists and biotech leaders working across pharmacology, translational research, and therapeutic development Curated intelligence on GPCR drug discovery trends and developments Expert-led webinars and masterclasses

He is the Research director at INSERM with a specific interest in G protein-coupled receptors by developing loss-of-function variants of the MT2 melatonin receptors that are associated with type 2 diabetes (TD2) development

Organizers Eurofins DiscoverX Eurofins DiscoverX is a one-stop-shop for GPCR drug discovery and development scientists and biotech leaders working across pharmacology, translational research, and therapeutic development Curated intelligence on GPCR drug discovery trends and developments Expert-led webinars and masterclasses

Will attending help with continuing education or professional development? Yes. These webinars are designed to support ongoing scientific development in GPCR pharmacology and drug discovery

His work is grounded in careful assay development and a conviction that the signaling space around a Vaccine development at scale — How to read a landscape of 90+ parallel vaccine candidates without confusing BRET-based platform for capturing downstream signaling, built with the Bouvier lab — illustrates how assay-development

Wisconsin-Madison and later in the Ploegh lab at Harvard Medical School and Boston Children's Hospital, he developed completed his postdoctoral training at MIT and Harvard Med School in the lab of Hidde Ploegh , where he developed Work in his independent laboratory is focused on developing new pharmacological tools via chemistry and

He has more than 20 years of experience in GPCR, primarily focused on drug discovery and developing new

properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic development

Robert Laprairie is an Associate Professor and the Saskatchewan Research Chair in Drug Discovery and Development

nervous system disorders realm to understand the neurobiology of neuropsychiatric disorders and to develop

His lab focuses on developing and innovating technologies to solve broad questions in pharmacology, with

We have developed an array of fluorescent biosensors to map kinase activity in living cells and are exploring

(MFI): a reliable, self-sustaining computational chemistry service provider, developing its own software

She developed expertise over the past two decades studying structure/function relationships of GPCRs

His current work is mainly focused on screening and assay development to bridge the gap between in vitro

Alice Ting developing programmable receptors for molecular sensing and controlling cellular behaviour

pathways, with the goal of identifying and targeting novel aspects of GPCR signaling for therapeutic development

She is an internationally recognized biophysicist for her contributions in developing constrained molecular

He has developed novel tools and methodologies to study fungal GPCRs which allowed the determination

He is passionate about developing more rational ways to understand and engineer biology.

The ultimate goal of Adriano’s research is to target novel aspects of GPCR signaling for therapeutic development

deciphering of cellular and organ functions, which require individual adhesion GPCRs, and extends to the development